(Q38899363)

7 September 2017

Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole (English)

1 reference

7 September 2017

0 references

Carmelo Massimo Maida

object named as

Carmelo Massimo Maida

2

0 references

Fiorenza Orlando

object named as

Fiorenza Orlando

4

0 references

author name string

Elisabetta Spreghini

1

1 reference

7 September 2017

Serena Tomassetti

3

1 reference

7 September 2017

Daniele Giannini

5

1 reference

7 September 2017

Maria Eleonora Milici

6

1 reference

7 September 2017

Giorgio Scalise

7

1 reference

7 September 2017

Francesco Barchiesi

8

1 reference

7 September 2017

language of work or name

English

0 references

publication date

7 April 2008

1 reference

Antimicrobial Agents and Chemotherapy

7 September 2017

1 reference

7 September 2017

52

1 reference

7 September 2017

6

1 reference

7 September 2017

1929-1933

1 reference

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia

7 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2415808

Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2415808

Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2415808

Epidemiology of invasive candidiasis: a persistent public health problem

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2415808

Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2415808

In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2415808

Posaconazole as salvage therapy for zygomycosis

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2415808

Posaconazole: a broad-spectrum triazole antifungal

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2415808

Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2415808

Application of real-time quantitative PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azoles

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2415808

Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2415808

In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2415808

Patterns of amphotericin B killing kinetics against seven Candida species.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2415808

Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program.

25 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2415808

Clinical significance of azole antifungal drug cross-resistance in Candida glabrata

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2415808

In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2415808

A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS

22 August 2018

1 reference

12 December 2020

Control of a Candida glabrata prosthetic endovascular infection with posaconazole

1 reference

12 December 2020

Successful treatment of disseminated fusariosis with posaconazole during neutropenia and subsequent allogeneic hematopoietic stem cell transplantation

1 reference

12 December 2020

Correlation of posaconazole minimum fungicidal concentration and time kill test against nine Candida species

1 reference

12 December 2020

Guidelines for treatment of candidiasis

1 reference

12 December 2020

Identifiers

DOI

10.1128/AAC.00130-08

1 reference

7 September 2017

1 reference

7 September 2017

PubMed publication ID

18391037

1 reference